Creating new antibody treatments for cancer
Official title: Development of Novel Antibody Conjugates for Cancer Immunotherapy
Funded at University of Wisconsin-Madison · NIH-11045678 · Data updated 2026-11-12
This study is exploring a new way to help cancer patients by creating special treatments that can find and break down certain proteins linked to cancer, which could make existing therapies work better for different types of tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $401,115 |
| NIH project number | 5R01CA284689-02 |
| Project ID | NIH-11045678 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that express specific extracellular proteins targeted by the novel antibody conjugates.
✕Less likely to help
Patients with cancers that do not express the targeted extracellular proteins may not receive any benefit from this research.
What this research studies
This research focuses on developing innovative antibody conjugates that can target and degrade specific proteins associated with cancer. By using a novel approach called LYTAC, the study aims to enhance the effectiveness of cancer immunotherapy by directing extracellular proteins to the lysosome for degradation. This method could potentially improve the treatment of various cancers by targeting proteins that are currently difficult to address with existing therapies. Patients may benefit from more effective cancer treatments that specifically target their tumor characteristics.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that specifically target and degrade harmful proteins in tumors.
How similar studies have gone: Other research has shown promise with similar approaches, particularly with PROTACs, indicating a potential for success with this novel method.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Tang, Weiping — University of Wisconsin-Madison
- Study coordinator: Tang, Weiping
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.